Private equity firm Thoma Bravo LLC has agreed to acquire Mediware for $195 million in a deal expected to close by the end of 2012. The $22 per share price is about 40 percent higher than the stock’s closing price on Sept. 11 of $15.75 per share.
Mediware is primarily known for its medication, blood bank and home health management systems. Expanding further into niche markets, the company in 2012 acquired blood management consultancy Strategic Healthcare Group, the Cyto Management System for chemotherapy, and stem cell transplantation software vendor Transtem.
Thoma Bravo currently invests in 14 software and technology companies, primarily serving multiple industries with such services as security, troubleshooting, integration, optimization, disaster recovery and compliance management. Hyland Software, an established document imaging and content management vendor serving health care and other industries, is in the portfolio.
Be the first to comment on this post using the section below.